Current and Future Application of Artificial Intelligence in Clinical Medicine E-Book
37,34 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Fachliteratur
- Sprache: Englisch
Current and Future Application of Artificial Intelligence in ClinicalMedicine presents updateson the application of machine learning and deep learning techniques in medicalprocedures. . Chapters in the volume have been written by outstandingcontributors from cancer and computer science institutes with the goal of providing updated knowledge to the reader. Topics covered in the bookinclude 1) Artificial Intelligence (AI) applications in cancer diagnosis and therapy,2) Updates in AI applications in the medical industry, 3) the use of AI in studyingthe COVID-19 pandemic in China, 4) AI applications in clinical oncology(including AI-based mining for pulmonary nodules and the use of AI inunderstanding specific carcinomas), 5) AI inmedical imaging. Each chapter presents information on related sub topics in areader friendly format. The combination of expert knowledge and multidisciplinary approaches highlightedin the book make it a valuable source of information for physicians andclinical researchers active in the field of cancer diagnosis and treatment(oncologists, oncologic surgeons, radiation oncologists, nuclear medicinephysicians, and radiologists) and computer science scholars seeking tounderstand medical applications of artificial intelligence.
Sie lesen das E-Book in den Legimi-Apps auf:
Seitenzahl: 253
Veröffentlichungsjahr: 2021
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is 1. the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Ltd. Executive Suite Y - 2 PO Box 7917, Saif Zone Sharjah, U.A.E. Email: [email protected]
PREFACE
Artificial intelligence (AI) brought me a breakthrough regarding clinical data and computer models. Nowadays, with the development of AI significantly advances progress, we hope the researcher can utilize this modern technology to improve clinical accuracy such as diagnosis, prognosis, therapeutic, and so on. Clinical work is filled enough with patients and they need AI help to minimize workload and improve the high efficiency of the medical assignment.
Titled “Current and Prevalent Trends in Clinical Medicine with Artificial Intelligence” this book included AI application in cancer diagnosis and prognosis, AI accelerates the development and transformation of the medical care AI in China’s COVID-19 Pandemic and AI experience of fighting with the COVID-19. All readers welcome to read. In this book, you can learn the AI technology with Clinical knowledge., the latest advance of AI application in the clinic, even now, it can be applied in the COVID-19 pandemic. We are trying to collect the latest issue regarding AI in Clinical Oncology.
In preparing this book we have had the privilege of collaborating with outstanding contributors from leading comprehensive cancer and computer specialist. We believe that the authors’ expertise, distinguished pieces of knowledge, and multidisciplinary approaches provide a valuable source of information and can guide decision-making for physicians and clinical researchers.
All physicians active in the field of cancer diagnosis and treatment (oncologists, oncologic surgeons, radiation oncologists, nuclear medicine physicians, and radiologists) and computer specialists on artificial intelligence are the target audience for this book. The book can also be used to train young specialists who are preparing for a multidisciplinary crossover examination.
We dedicate this book to those who treat people with dignity and respect and to organizations and individuals committed to building a peaceful world.
ACKNOWLEDGEMENT
Shaanxi Jiuzhou Biomedical Science and Technology Group referred to as “Jiuzhou Group”, founded in September 2006, is located in Xi'an Hi-tech Development Zone in China established by Shaanxi Jiuzhou Biotechnology Co., Ltd. and Shaanxi high tech Industry Investment Co., Ltd. Main business: research and development and transformation of cell biotechnology, professional platform service of life science, precision medical diagnosis, medical service, health management, etc. Jiuzhou Group began to invest in the construction of Shaanxi Jiuzhou biomedical science and Technology Park (currently, knew as Shaanxi Jiuzhou stem cell science and Technology Industrial Park) in 2002, which is a provincial key construction project in the 11th five year plan. At the beginning of the 12th Five Year Plan period, the first industrial transformation platform of cell gene was built in China (2010), and the whole industrial chain of cell collection, storage, detection, production and preparation, clinical research and application was built. After ten years of accumulation, the industrial pattern of "one park, one chain and one center" has been formed in Jiuzhou stem cell science and Technology Industrial Park, whole industrial chain of cell biology and Jiuzhou medical center.
Xi 'an Zer Huier Education Technology Co., Ltd., founded in 2018, in China, is a professional institution focusing on medical and health examination and training and improving the professional ability of the pharmaceutical industry. The company has the most professional team of teachers, all the lecturers are from domestic and foreign professional colleges and universities. They not only have made a lot of achievements in the relevant fields, but also have a wealth of teaching experience, focusing on the systematic training of professionals in the field of health care, to provide more breadth, validity, and professional training services for the field of health care in China.
List of Contributors
Artificial Intelligence (AI) in Cancer Diagnosis and Prognosis
Parsa Mahmood Dar1,*,Amara Dar2,Komal Hayat3Abstract
Cancer is a disorder with aggressive, low-median survival. Unfortunately, the healing time is long and expensive owing to high recurrence and mortality rates. It is essential to increase patient survival. Over the years, mathematical and computer engineering advancements have inspired numerous scientists to use quantitative methods to evaluate disease prognosis, such as multivariate statistical analysis, and the precision of these studies is considerably higher than that of observational predictions. However, as artificial intelligence (AI) has found widespread applications in clinical cancer research in recent years, especially machine learning and deep learning, cancer prediction output has reached new heights. The literature on the use of AI for cancer diagnosis and prognosis is discussed in this part. We discuss how AI supports the diagnosis of cancer, especially in terms of its unparalleled precision. We also illustrate forms in which these approaches progress the field. Opportunities and problems are addressed in the clinical application of AI.
1. INTRODUCTION
By allowing significant changes in communication, transportation, and media, Artificial Intelligence (AI) and Machine Learning (ML) have an enormous effect on our daily lives. AI has also recently achieved incredible heights in the science of clinical cancer. It is used to help in cancer diagnosis and prognosis, considering its unparalleled degree of sensitivity, far higher than that of a general statistical expert [1].
The most complex disease condition of all is cancer, which may be malignant. Numbers for 2018 showed around 9.6 million cancer deaths worldwide. Although the incidence of cancer mortality from the US has been estimated to decrease by 27%, this evidence does not reassure the present estimates since the number of cases of cancer reported each year has not decreased [2]. Almost 1.7 million new cases of cancer were reported in 2019, and 0.6 million deaths were recorded. It is necessary to study and practise such clinical techniques that help minimise the likelihood of mortality, considering the current scenario. The technology of AI for healthcare reform flourishes every day. Large data can be learned and understood from this scientific breakthrough [3].
In the early stages, cancer is impossible to diagnose, and there are chances of recurrence after treatment. In comparison, precise, high-security disease predictions are very difficult. A simple search of the literature shows that the number of research papers on cancer has increased exponentially, especially those involving AI tools and large databases containing historical clinical cases for AI models [4]. In retrospective trials, the common approach is to obtain basic clinical results along through the use of the traditional TNM staging system (based on tumour size (T), the spread of cancer to nearby lymph nodes (N), and the spread of cancer to other parts of the body (M, for metastasis), yet incorrect prognosis seems to be a bottleneck for clinicians [5].
Given the importance of time for cancer patients, AI has been widely used in clinical cancer studies over the years due to its usefulness and advantages. The present study selected and analysed PubMed, Google Scholar, CNKI, and WANFANG datasets from 1995-2019. Using matching keywords, 3594 papers were identified to be related to AI cancer studies in these databases. One thousand one hundred thirty-six documents, from a total of 2458 papers, were found similar and deleted. These papers were further examined for relevance using their headings/abstracts, and 2365 papers were deemed significant. We included 126 full-text papers on cancer detection and prognosis utilizing AI using a forward citation search [6].
As vast numbers of cancer-diagnosed patients and those who have endured multiple treatments have accrued through the years, it is possible that early cancer diagnosis will be improved using this archive.
2. MAJOR CANCER TYPE
Men are mostly vulnerable to prostate, colorectal, and lung cancers. Together, they account for 42 percent of all diagnoses in adults, with almost 1 in 5 new cases of prostate cancer alone.
For women, breast, prostate, and colorectal cancer are the three most prevalent cancers. Together, they account for half of all incidents, with 30% of new cases of breast cancer alone.
Such malignancies also blame for the largest number of casualties. Lung cancer accounts for almost one-quarter of all cancer deaths recorded worldwide. Data published by ourworldindata.org/cancer shows deaths reported by different cancers as well as internationally as shown in Fig. (1).
Fig. (1)) Death caused globally due to cancers reported in 2017 [7].2.1. Lung Cancer
Uncontrolled cell proliferation of lung tissues is the cause of lung cancer. From 1990 to 2016, mortality rates attributed to lung cancer decreased by 48 percent among men and 23 percent among women from 2002 to 2016. The number of new cases of lung cancer fell by 3 percent per year in men and 1.5 percent per year in women from 2011 to 2015. The disparities represent past trends in the usage of cigarettes, where several years later, women started smoking in significant numbers than women. Smoking habits do not seem to justify the higher lung cancer incidences recorded in women relative to men born around the 1960s [2] as shown in Fig. (2).
Fig. (2)) Cancerous growth in lungs as diagnosed by AI [8]. An intelligent software system for lung cancer diagnostics has been developed by researchers from Peter the Great St.Petersburg Polytechnic University (SPbPU). The system analyzed anonymized CT images of 60 patients at the Oncological Center, and the focal nodules in lungs of small sizes (2 mm) could be successfully found.2.2. Breast Cancer
Although breast cancer can occur in males and females, it is more potent in females. From 1989 to 2016, breast cancer mortality rates of women plunged 40%. This risk reduction is attributed to developments in early detection. The use of DNN as a breast cancer tool has been recorded with 96% precision [6] as shown in Fig. (3).
2.3. Prostate Cancer
It is the most prevalent type of cancer in men but not necessarily fatal. Many patients with prostate cancer die from this malignancy rather than collapse. Death rates for male prostate cancer dropped to 51% from 1993 till 2016. Owing to high over-diagnosis rates, routine screening with PSA blood testing is no longer recommended. Therefore, fewer prostate cancer reports are found [2] as shown in Fig. (4).
Fig. (3)) Breast cancer imaging using AI [9]. IEEE fellow Karen Panetta has built an AI technology to distinguish breast cancer cells from non-cancer cells by analyzing biopsy images. If a cancer is present, the AI tool will also determine the grade of cancer. Fig. (4)) AI helping early diagnosis of prostate cancer [10]. Radboud University Medical Center researchers have advanced a “deep learning” system that is more accurate than most pathologists in determining the aggressiveness of prostate cancer. The AI system, based on data from more than 1,200 patients, self-diagnoses itself to identify prostate cancer using tissue samples for diagnosis.2.4. Colorectal Cancer
Colorectal cancer death rates declined by 53% from 1970 to 2016, thanks to increased screening and treatment advancements. Since the mid-1990s, however, new cases of colorectal cancer have increased by around 2 percent per year in people younger than age 55 [11] Fig. (5).
Fig. (5)) Colorectal cancer diagnosis using AI [12]. AI has shown promising results in terms of accuracy in diagnosing CRC. However, the size and quality of training and validation datasets from most studies are relatively limited to apply the technology to clinical practice. In addition, external cross-validation is needed, especially for tumor classification.2.5. Development in Diagnostic Tools
The decline in the death rate of cancer patients has been determined over time to be closely linked to early detection and adequate care [13]. The current technique is to use AI to achieve outcomes faster than the classical methods of diagnosis. The invention of the Virtual Reality Microscope (ARM) would continue to increase the functioning of the current procedure since it will be cost-effective, with readily accessible materials without the requirement for the study of whole slide graphical representations of the tissue.
Chinese researchers used detailed segmentation of brain tumours in AI and machine learning [14, 15]. For the detection of brain tumour and the assessment of surgical alternatives, tumour segmentation is important. Surgeons usually manually conduct personalised tumour segmentation, but their findings are not consistent. The results are correct, accurate, and reliable, preferring the usage of this established method.
SOPHiA GENETICS provides genomic software specifically developed to precisely classify the diverse mutational environment of large solid tumours such as lung, colorectal, skin, and brain cancers. They have licensed an AI-based cancer test kit that analyses patient DNA samples. It will accurately identify mutations/alterations in 42 genes related to solid cancers.
Tumours are either benign or malignant; not all tumours are cancerous. Recently, researchers from the University of Southern California's Viterbi School of Engineering have trained a machine-learning algorithm to distinguish between benign and malignant tumors for synthetic samples of breast cancer with an 80% accuracy rate.
In the study of the mammogram images and for the accurate diagnosis of breast cancer, Yala and his team evaluated and compared the diagnostic abilities of both the TC model and the coevolutionary neural network (new algorithm) and concluded that it dramatically enhanced risk discrimination [16].
Global developments in medical science in regions such as China, the USA, and Europe have demonstrated that AI requires time for adequate and prompt detection and detailed and reliable prognosis of deadly diseases such as cancer. Cancer prognosis provides estimates of recurrence of diseases and recovery of patients, with the goal of enhancing patient management [17, 18].
To evaluate the data collected from cancer patients, various mathematical models were used. By maintaining and reproducing the data, AI made the job simpler. Enshaei A et al. [19] contrasted a number of algorithms and classifiers with traditional statistical logistic regression approaches to demonstrate that AI may play a role in providing prognostic and predictive approaches.
3. Artificial Intelligence (AI) in Precision Medicine
Precision medicine theory operates on a customised patient care treatment approach based on the genomic understanding of the disease. This counselling method is not new, but patients with the same symptoms are usually treated on the same lines, ignoring the fact that each person has different responses due to different genetic compositions. A personalised medicinal approach that lets doctors select the patient's best treatment option is precision medicine or tailored medicine.
AI makes remarkable advances in drug discovery techniques, designing drugs, effectiveness of drugs’ action, exposing molecular drug pathways, co-relating popular conditions, and analysing the most responsive patient population for a particular treatment. After 2016, various pharmaceutical corporations worldwide (such as Pfizer, IBM Watson, Exscientia) have partnered to develop active immune-modulating agents to give prospective patients new immune-oncology therapies. Exscientia, a UK-based company, leads the world of drug growth, researching various aspects of AI to create innovative medicines. They are the pioneers in drug synthesis process automation. GSK and Sanofi partnered with Exscientia to determine particular cancer goals and set specific medicines against these targets [20].
Overall, researchers use AI in the area of cancer diagnosis and customised medicine for identifying the best care options for cancer patients as shown in Tables 1 and 2. Although excellent results are coming, thorough research is still needed to further improve outcomes [54-57].
4. Challenges for AI in Cancer Treatment
However, precision, accuracy and efficiency of AI and machine learning have been established in the diagnosis and prognosis of various cancers; in certain contexts, this method aids in the early diagnosis of cancer-related lethal diseases and has resulted in reducing the reported mortality rates linked to multiple type of cancers . But there is still a long way to go. To ensure its application in cancer diagnosis and prognosis, AI faces certain hurdles to address [58].
Since images from medical imaging would not be used directly as input data, to maintain the precision and quality of the operation, it is necessary to retrieve and process features from the pictorial data by applying different mathematical models [59
